The head of Pfizer announced the refusal of poor countries to purchase vaccines

Low- and middle-income countries chose not to order the vaccine developed by Pfizer and BioNTech, Pfizer CEO Albert Burla said in a letter to staff.

“Fair and equitable distribution [of the vaccine] has been a guiding light” for the company from day one, he said. In order for each country to receive the drug, two conditions had to be met: to ensure an adequate price and sufficient production volume, Burla noted.

As a result, the company offered countries a multi-level pricing system. For middle-income countries, the vaccine cost half as much as for the rich, and for low-income countries, the drug was offered at cost, Burla said.

Despite this, rich countries have reserved most of the doses, the head of Pfizer noted. However, when he noticed this, he decided to once again approach "many heads" of middle- and low-income countries to once again invite them to reserve doses of the vaccine, since the supply was limited. However, they, according to Burla, decided to place orders with other manufacturers of covid-19 drugs .